Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan acquired 90,300 shares of the firm's stock in a transaction on Tuesday, November 12th. The stock was purchased at an average price of C$5.13 per share, for a total transaction of C$463,672.44.
Sime Armoyan also recently made the following trade(s):
- On Monday, September 16th, Sime Armoyan sold 300,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00.
Knight Therapeutics Trading Down 0.6 %
Knight Therapeutics stock traded down C$0.03 during mid-day trading on Friday, hitting C$5.19. The company's stock had a trading volume of 103,432 shares, compared to its average volume of 69,560. The stock has a market cap of C$525.28 million, a price-to-earnings ratio of -26.10, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The business has a 50 day moving average price of C$5.72 and a 200-day moving average price of C$5.74. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. Knight Therapeutics Inc. has a 12 month low of C$5.07 and a 12 month high of C$6.23.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the company. Stifel Nicolaus raised Knight Therapeutics from a "hold" rating to a "buy" rating and increased their price target for the stock from C$5.75 to C$6.75 in a research report on Tuesday, August 13th. Raymond James lowered their target price on Knight Therapeutics from C$8.00 to C$7.50 in a research report on Thursday. Finally, Stifel Canada upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 12th.
Read Our Latest Stock Analysis on Knight Therapeutics
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
